A Comprehensive Board Review in Hematology and Medical Oncology

1. Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology.
2. Utilize current standards of care for patients with cancer, blood disorders and malignancies.
3. Demonstrate proficiency of knowledge in hematology and medical oncology.
4. Incorporate recent advances in management of hematologic and oncologic patients.

A Virtual Live Streaming Course

The Comprehensive Board Review in Hematology and Medical Oncology will be virtual. This program will be presented only as a live streaming course.

More information and registration will follow on a later date.

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

American Board of Internal Medicine (ABIM)
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 50.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

In order to receive MOC points, you must pass the post-test with a score of 70% or higher.

Participant completion data will be shared with and transmitted to the ACCME on the participant’s behalf. 

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Sharon H. Giordano, MD, FASCO
Professor
The University of Texas MD Anderson Cancer Center

Co-Director

Nothing to disclose

Tapan M. Kadia, MD
Professor
The University of Texas MD Anderson Cancer Center

Co-Director

Grant or research support-Bristol-Myers Squibb Company|Honoraria-DAVA Oncology|Speakers Bureau-CURE|Honoraria-DrenBio|Grant or research support-Dren Bio|Grant or research support-Celgene Corporation (Relationship has ended)|Grant or research support-BMS|Honoraria-Biologix (Relationship has ended)|Grant or research support-Janssen Biotech, Inc. (Relationship has ended)|Grant or research support-Incyte Corporation|Grant or research support-Astex|Grant or research support-Abcuro|Grant or research support-Pfizer Inc.|Honoraria-Hikma Pharmaceuticals|Consulting Fee-Genzyme Corporation (Relationship has ended)|Grant or research support-Glycomimetics|Consulting Fee-Sellas|Grant or research support-Sellas|Grant or research support-AbbVie Inc.|Grant or research support-Amgen Inc. (Relationship has ended)|Grant or research support-Genentech, Inc.|Grant or research support-Ascentage|Grant or research support-Cellenkos (Relationship has ended)|Grant or research support-AstraZeneca US (Relationship has ended)|Grant or research support-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended)|Paid consultant-AbbVie Inc.|Paid consultant-Genentech, Inc.|Grant or research support-Genfleet|Grant or research support-Sellas, Inc|Grant or research support-Delta Fly Pharma (Relationship has ended)|Grant or research support-Jazz Pharmaceuticals|Paid consultant-Jazz Pharmaceuticals|Paid consultant-Novartis Pharmaceuticals Corporation|Paid consultant-Daiichi Sankyo, Inc.|Paid consultant-Agios Pharmaceuticals Inc.|Consulting Fee-PinotBio (Relationship has ended)|Consulting Fee-Sanofi US (Relationship has ended)|Paid consultant-Pfizer Inc.|Grant or research support-Regeneron Pharmaceuticals, Inc.|Consulting Fee-Servier Pharmaceuticals|Consulting Fee-Syndax|Consulting Fee-Kura

Martha Mims, MD, PhD
Professor and Section Chief, Hematology/Oncology
Baylor College of Medicine

Co-Director

Stocks or stock options, excluding diversified mutual funds-Amgen Inc.|Stocks or stock options, excluding diversified mutual funds-Biogen Inc.|Grant or research support-Janssen Biotech, Inc.|Grant or research support-Celgene Corporation|Grant or research support-Incyte Corporation|Grant or research support-inovio

Nishin Bhadkamkar, MD
Associate Professor
The University of Texas MD Anderson Cancer Center

Other Planning Committee Member

Nothing to disclose

Felisha Estelle, BBA
CE Activity Planner
The University of Texas MD Anderson Cancer Center

Other Planning Committee Member

Nothing to disclose

Alessandra Ferrajoli, MD
Professor of Medicine
The University of Texas MD Anderson Cancer Center

Other Planning Committee Member

Membership on Advisory Committees or Review Panels, Board Membership, etc.-AbbVie Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US (Relationship has ended)

Shreyaskumar Patel, MD
Professor - Sarcoma Medical Oncology
The University of Texas MD Anderson Cancer Center

Other Planning Committee Member

Consulting Fee-Daiichi Sankyo, Inc.|Consulting Fee-Deciphera|Consulting Fee-Kura Oncology